Typically affecting older dogs, new research studies the benefits of paricalcitol, a drug used for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney failure.

VDRAs can be used to manage secondary hyperparathyroidism at all stages of CKD and are likely to have additional benefits beyond the control of mineral and bone disorders, as has been shown in ...

Cinacalcet (Sensipar ® /Mimpara ®, Amgen Inc., Thousand Oaks, CA), the first-in-class calcimimetic agent approved for treatment of secondary hyperparathyroidism in dialysis patients, is ...

Hebrew University researchers test paricalcitol for treating CKD in dogs, showing promise against proteinuria. Study ...

Secondary hyperparathyroidism is characterized by normal calcium but high parathyroid hormone levels, whereas pseudohypoparathyroidism is associated with low calcium and high parathyroid hormone ...